Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a small molecule inhibitor, specifically targeting **Aurora kinase C** and **Glycogen synthase kinase-3 beta (GSK-3β)**. It belongs to the quinazolinamine class of compounds.
- Other names
- (5-METHYL-1H-PYRAZOL-3-YL)-(2-PHENYLQUINAZOLIN-4-YL)AMINEGSK3i XIIIGSK-3i XIIIGSK 3i XIIIGSK-3 INHIBITOR XIIIGSK3 INHIBITOR XIIIGSK 3 INHIBITOR XIII
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)AURKC (Aurora kinase C)
Beyond the preview
Go deeper on N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE.